These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35877814)

  • 1. Elevated Plasma Phosphorylated Tau 181 in Amyotrophic Lateral Sclerosis.
    Cousins KAQ; Shaw LM; Shellikeri S; Dratch L; Rosario L; Elman LB; Quinn C; Amado DA; Wolk DA; Tropea TF; Chen-Plotkin A; Irwin DJ; Grossman M; Lee EB; Trojanowski JQ; McMillan CT
    Ann Neurol; 2022 Nov; 92(5):807-818. PubMed ID: 35877814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated plasma p-tau181 levels unrelated to Alzheimer's disease pathology in amyotrophic lateral sclerosis.
    Vacchiano V; Mastrangelo A; Zenesini C; Baiardi S; Avoni P; Polischi B; Capellari S; Salvi F; Liguori R; Parchi P;
    J Neurol Neurosurg Psychiatry; 2023 Jun; 94(6):428-435. PubMed ID: 37012065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phosphorylated tau in plasma could be a biomarker of lower motor neuron impairment in amyotrophic lateral sclerosis.
    Verde F; Milone I; Colombo E; Maranzano A; Dubini A; Colombrita C; Gentile F; Doretti A; Torre S; Messina S; Morelli C; Torresani E; Poletti B; Priori A; Maderna L; Ratti A; Silani V; Ticozzi N
    Neurol Sci; 2023 Oct; 44(10):3697-3702. PubMed ID: 37369876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
    Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
    JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic-prognostic value and electrophysiological correlates of CSF biomarkers of neurodegeneration and neuroinflammation in amyotrophic lateral sclerosis.
    Abu-Rumeileh S; Vacchiano V; Zenesini C; Polischi B; de Pasqua S; Fileccia E; Mammana A; Di Stasi V; Capellari S; Salvi F; Liguori R; Parchi P;
    J Neurol; 2020 Jun; 267(6):1699-1708. PubMed ID: 32100123
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Plasma Biomarkers for A/T/N Classification of Alzheimer Disease Among Adults of Caribbean Hispanic Ethnicity.
    Honig LS; Kang MS; Lee AJ; Reyes-Dumeyer D; Piriz A; Soriano B; Franco Y; Coronado ZD; Recio P; Mejía DR; Medrano M; Lantigua RA; Teich AF; Dage JL; Mayeux R
    JAMA Netw Open; 2023 Apr; 6(4):e238214. PubMed ID: 37079306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
    JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of Fully Automated CSF and Novel Plasma Biomarkers With Alzheimer Disease Neuropathology at Autopsy.
    Grothe MJ; Moscoso A; Ashton NJ; Karikari TK; Lantero-Rodriguez J; Snellman A; Zetterberg H; Blennow K; Schöll M;
    Neurology; 2021 Sep; 97(12):e1229-e1242. PubMed ID: 34266917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid-Beta Co-Pathology Is a Major Determinant of the Elevated Plasma GFAP Values in Amyotrophic Lateral Sclerosis.
    Mastrangelo A; Vacchiano V; Zenesini C; Ruggeri E; Baiardi S; Cherici A; Avoni P; Polischi B; Santoro F; Capellari S; Liguori R; Parchi P
    Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer's disease pathology and clinical disease progression.
    Clark C; Lewczuk P; Kornhuber J; Richiardi J; Maréchal B; Karikari TK; Blennow K; Zetterberg H; Popp J
    Alzheimers Res Ther; 2021 Mar; 13(1):65. PubMed ID: 33766131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.
    Cousins KAQ; Shaw LM; Chen-Plotkin A; Wolk DA; Van Deerlin VM; Lee EB; McMillan CT; Grossman M; Irwin DJ
    JAMA Neurol; 2022 Nov; 79(11):1155-1164. PubMed ID: 36215050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Underestimated Relevance of Alzheimer's Disease Copathology in Amyotrophic Lateral Sclerosis.
    Barba L; Otto M; Abu-Rumeileh S
    J Alzheimers Dis; 2023; 95(4):1401-1404. PubMed ID: 37807784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimation of Tau and Phosphorylated Tau181 in Serum of Alzheimer's Disease and Mild Cognitive Impairment Patients.
    Shekhar S; Kumar R; Rai N; Kumar V; Singh K; Upadhyay AD; Tripathi M; Dwivedi S; Dey AB; Dey S
    PLoS One; 2016; 11(7):e0159099. PubMed ID: 27459603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Electrochemical impedance-based biosensor for label-free determination of plasma P-tau181 levels for clinically accurate diagnosis of mild cognitive impairment and Alzheimer's disease.
    Tieu MV; Choi SH; Le HTN; Cho S
    Anal Chim Acta; 2023 Sep; 1273():341535. PubMed ID: 37423666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic Performance and Clinical Applicability of Blood-Based Biomarkers in a Prospective Memory Clinic Cohort.
    Sarto J; Ruiz-García R; Guillén N; Ramos-Campoy Ó; Falgàs N; Esteller D; Contador J; Fernández G; González Y; Tort-Merino A; Juncà-Parella J; Bosch B; Borrego-Écija S; Molina-Porcel L; Castellví M; Vergara M; Antonell A; Augé JM; Naranjo L; Sanchez-Valle R; Lladó A; Balasa M
    Neurology; 2023 Feb; 100(8):e860-e873. PubMed ID: 36450604
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease.
    Kac PR; Gonzalez-Ortiz F; Simrén J; Dewit N; Vanmechelen E; Zetterberg H; Blennow K; Ashton NJ; Karikari TK
    Alzheimers Res Ther; 2022 May; 14(1):65. PubMed ID: 35545792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phospho-specific plasma p-tau181 assay detects clinical as well as asymptomatic Alzheimer's disease.
    De Meyer S; Vanbrabant J; Schaeverbeke JM; Reinartz M; Luckett ES; Dupont P; Van Laere K; Stoops E; Vanmechelen E; Poesen K; Vandenberghe R
    Ann Clin Transl Neurol; 2022 May; 9(5):734-746. PubMed ID: 35502634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Associations of plasma phosphorylated tau181 and neurofilament light chain with brain amyloid burden and cognition in objectively defined subtle cognitive decline patients.
    Huang Y; Li Y; Xie F; Guo Q
    CNS Neurosci Ther; 2022 Dec; 28(12):2195-2205. PubMed ID: 36074638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.